Virtual Poster Session in Gastrointestinal Cancers
Virtual Poster
Virtual Poster

Virtual Poster Session in Gastrointestinal Cancers

Practical Application of Key Data Presented During the 2018 Gastrointestinal Cancers Symposium in San Francisco

Not a member of My prIME? Join now for instant access.

View CME-certified poster presentations and downloadable slides covering the most up-to-date clinical trial data from the 2018 Gastrointestinal Cancers Symposium in San Francisco.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.5 AMA PRA Category 1 Credits

Release Date

Release Date

Jan 26, 2018

Expiration Date

Jan 26, 2019

Colorectal Cancer

Thierry Andre, MD

Abstract #553: Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142

Featured Expert: Thierry Andre, MD

Johanna Bendell, MD

Abstract #560: A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC)

Featured Expert: Johanna Bendell, MD

Tanios Bekaii-Saab, MD, FACP

Abstract #611: Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)—An ACCRU Network study

Featured Expert: Tanios Bekaii-Saab, MD, FACP

Eric Van Cutsem, MD, PhD

Abstract #627: BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers

Featured Expert: Eric Van Cutsem, MD, PhD

Toshihiro Kudo, MD, PhD

Abstract #821: Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy

Featured Expert: Toshihiro Kudo, MD, PhD

Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA

Abstract #207: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial

Featured Expert: Ghassan Abou-Alfa, MD, MBA

Andrew X. Zhu, MD, PhD

Abstract #209: KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Featured Expert: Andrew X. Zhu, MD, PhD

Jordi Bruix, MD, PhD

Abstract #412: Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib

Featured Expert: Jordi Bruix, MD, PhD

Neuroendocrine Tumors

Edward M. Wolin, MD

Abstract #347: Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients

Featured Expert: Edward M. Wolin, MD

Jaswinder Singh, MD

Abstract #382: Phase 2 study of carfilzomib for the treatment of patients with advanced neuroendocrine cancers

Featured Expert: Jaswinder Singh, MD

Joseph S. Dillon, MD

Abstract #395: Time to sustained improvement in bowel movement frequency with telotristat ethyl: Analysis of the phase III telecast study

Featured Expert: Joseph S. Dillon, MD

Faculty

  • Ghassan Abou-Alfa, MD, MBAMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Thierry Andre, MDHôpital Saint Antoine
    Paris, France
  • Tanios Bekaii-Saab, MD, FACPMayo Clinic
    Phoenix, Arizona, United States
  • Johanna Bendell, MDSarah Cannon Research Institute
    Nashville, Tennessee, United States
  • Jordi Bruix, MD, PhDUniversity of Barcelona
    Barcelona, Spain
  • Joseph S. Dillon, MDUniversity of Iowa
    Iowa City, Iowa, United States
  • Toshihiro Kudo, MD, PhDOsaka University
    Osaka, Japan
  • Jaswinder Singh, MDMidwest Oncology Associates
    Kansas City, Missouri, United States
  • Eric Van Cutsem, MD, PhDUniversity Hospitals Leuven
    Leuven, Belgium
  • Edward M. Wolin, MDMontefiore Einstein Center for Cancer Care
    New York, New York, United States
  • Andrew X. Zhu, MD, PhDMassachusetts General Hospital
    Boston, Massachusetts, United States

This activity is specifically designed to meet the needs of practicing medical oncologists and other healthcare professionals involved in the treatment of patients with gastrointestinal malignancies.

After successful completion of this educational activity, participants should be able to:

  • Evaluate emerging clinical trial data in gastrointestinal malignancies, including studies focused on the safety and efficacy of novel targeted therapies

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Ipsen Biopharmaceuticals Inc.; and Merck and Co, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Virtual Poster Session in Gastrointestinal Cancers - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Abou-Alfa has disclosed that he has received consulting fees from Agios Pharmaceuticals; Amgen; Aptus Pharmaceuticals, Inc.; ASLAN Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Bayer; Bristol-Myers Squibb; Boston Scientific Corporation; CARsgen Therapeutics; CASI Pharmaceuticals, Inc.; Celgene Corporation; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; Delcath Systems Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Halozyme, Inc.; Inovio Pharmaceuticals, Inc.; Ipsen; Merck & Co., Inc.; MedImmune; Onxeo; PCI Biotech; sanofi-aventis; Servier; Silenseed; SillaJen Inc; Sirtex; and Yakult Pharmaceutical Industry. He has received grant/research support from Agios Pharmaceuticals; Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; CASI Pharmaceuticals, Inc.; Celgene Corporation; Exelixis; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Incyte Corporation; Lilly; MabVax Therapeutics Holdings, Inc.; MedImmune; Momenta Pharmaceuticals; and OncoMed Pharmaceuticals. (Research support to Institution).

Dr Andre has disclosed that he has received consulting fees and performed contracted research for or received research support from Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Bekaii-Saab has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Bendell has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Bruix has disclosed that he has received consulting fees from Bayer HealthCare Pharmaceuticals, Inc. and Eisai. He has also performed contracted research for or received research support from Bayer HealthCare Pharmaceuticals, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Dillon has disclosed that he has performed contracted research for or received research support from Lexicon. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kudo has disclosed that he has performed contracted research for or received research support from Bayer HealthCare Pharmaceuticals, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Singh has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Van Cutsem has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wolin has disclosed that he has received consulting fees from Advanced Accelerator Applications, Ipsen, Lexicon, and Novartis Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Zhu has disclosed that he has received consulting fees from Bayer HealthCare Pharmaceuticals, Inc. and Novartis Oncology. He has also disclosed performing contracted research for or receiving research support from Bristol-Myers Squibb and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.